Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Allergic Rhinitis
Conditions
Allergic Rhinitis, Perennial Allergic Rhinitis
Trial Timeline
Aug 1, 2009 → May 1, 2010
NCT ID
NCT00953147About Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + Placebo
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00953147. Target conditions include Allergic Rhinitis, Perennial Allergic Rhinitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00953147 | Phase 3 | Completed |
Competing Products
20 competing products in Allergic Rhinitis